SG10202012434QA - Methods of treating pancreatic cancer - Google Patents
Methods of treating pancreatic cancerInfo
- Publication number
- SG10202012434QA SG10202012434QA SG10202012434QA SG10202012434QA SG10202012434QA SG 10202012434Q A SG10202012434Q A SG 10202012434QA SG 10202012434Q A SG10202012434Q A SG 10202012434QA SG 10202012434Q A SG10202012434Q A SG 10202012434QA SG 10202012434Q A SG10202012434Q A SG 10202012434QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- pancreatic cancer
- treating pancreatic
- treating
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349217P | 2016-06-13 | 2016-06-13 | |
| US201662382689P | 2016-09-01 | 2016-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202012434QA true SG10202012434QA (en) | 2021-01-28 |
Family
ID=60663739
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810940XA SG11201810940XA (en) | 2016-06-13 | 2017-06-13 | Methods of treating pancreatic cancer |
| SG10202012434QA SG10202012434QA (en) | 2016-06-13 | 2017-06-13 | Methods of treating pancreatic cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810940XA SG11201810940XA (en) | 2016-06-13 | 2017-06-13 | Methods of treating pancreatic cancer |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3468548B1 (en) |
| JP (3) | JP7083214B2 (en) |
| KR (2) | KR20230047210A (en) |
| CN (1) | CN109562086A (en) |
| AU (1) | AU2017283491B2 (en) |
| BR (1) | BR112018075660A2 (en) |
| CA (1) | CA3026515A1 (en) |
| ES (1) | ES2895749T3 (en) |
| IL (1) | IL263508B2 (en) |
| MX (1) | MX2018015172A (en) |
| RU (1) | RU2768479C2 (en) |
| SG (2) | SG11201810940XA (en) |
| WO (1) | WO2017218544A1 (en) |
| ZA (1) | ZA201808258B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| EP3468548B1 (en) * | 2016-06-13 | 2021-08-04 | ChemoCentryx, Inc. | Methods of treating pancreatic cancer |
| WO2020060247A1 (en) * | 2018-09-19 | 2020-03-26 | 오토텔릭바이오 주식회사 | Anticancer composition |
| WO2022042537A1 (en) * | 2020-08-24 | 2022-03-03 | 江苏恒瑞医药股份有限公司 | APPLICATION OF COMBINATION OF FUSION PROTEIN OF TGF-β RECEPTOR AND MULTI-TARGETED TYROSINE KINASE INHIBITOR IN PREPARING ANTI-TUMOR DRUG |
| WO2023040804A1 (en) * | 2021-09-14 | 2023-03-23 | 信达生物制药(苏州)有限公司 | Pharmaceutical composition of anti-pd-1 antibody and chemotherapy agent and method for using same |
| CN115521913B (en) * | 2022-02-22 | 2023-07-25 | 北京景达生物科技有限公司 | NK cells and CD20, CD38 and Her2 antibodies combined application |
| CN116804221B (en) * | 2023-08-23 | 2023-11-03 | 汲迈生命科技(苏州)有限公司 | Application of LMO7 expression level in prediction of pancreatic cancer gemcitabine resistance |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52010B (en) * | 2005-06-22 | 2012-04-30 | Plexxikon Inc. | Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors |
| US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| EP2099454A4 (en) * | 2006-11-17 | 2010-11-10 | Abbott Lab | Aminopyrrolidines as chemokine receptor antagonists |
| US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| PL2175859T3 (en) * | 2007-07-12 | 2012-09-28 | Chemocentryx Inc | Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation |
| CA2709806A1 (en) * | 2008-01-22 | 2009-07-30 | Merck Patent Gmbh | Protein kinase inhibitors and use thereof |
| TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| MX2012006964A (en) * | 2009-12-17 | 2012-07-17 | Boehringer Ingelheim Int | New ccr2 receptor antagonists and uses thereof. |
| US8916601B2 (en) * | 2012-02-29 | 2014-12-23 | Chemocentryx, Inc. | Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides |
| US10189777B2 (en) * | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
| EP3468548B1 (en) | 2016-06-13 | 2021-08-04 | ChemoCentryx, Inc. | Methods of treating pancreatic cancer |
-
2017
- 2017-06-13 EP EP17813938.2A patent/EP3468548B1/en active Active
- 2017-06-13 RU RU2019100220A patent/RU2768479C2/en active
- 2017-06-13 CA CA3026515A patent/CA3026515A1/en active Pending
- 2017-06-13 SG SG11201810940XA patent/SG11201810940XA/en unknown
- 2017-06-13 ES ES17813938T patent/ES2895749T3/en active Active
- 2017-06-13 KR KR1020237010335A patent/KR20230047210A/en not_active IP Right Cessation
- 2017-06-13 WO PCT/US2017/037264 patent/WO2017218544A1/en unknown
- 2017-06-13 BR BR112018075660-1A patent/BR112018075660A2/en active Search and Examination
- 2017-06-13 KR KR1020197000640A patent/KR20190017913A/en not_active IP Right Cessation
- 2017-06-13 SG SG10202012434QA patent/SG10202012434QA/en unknown
- 2017-06-13 CN CN201780049675.7A patent/CN109562086A/en active Pending
- 2017-06-13 MX MX2018015172A patent/MX2018015172A/en unknown
- 2017-06-13 JP JP2018565305A patent/JP7083214B2/en active Active
- 2017-06-13 AU AU2017283491A patent/AU2017283491B2/en active Active
-
2018
- 2018-12-05 IL IL263508A patent/IL263508B2/en unknown
- 2018-12-06 ZA ZA2018/08258A patent/ZA201808258B/en unknown
-
2020
- 2020-06-15 JP JP2020103105A patent/JP2020147601A/en not_active Withdrawn
- 2020-06-15 JP JP2020103107A patent/JP2020147602A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2895749T3 (en) | 2022-02-22 |
| WO2017218544A1 (en) | 2017-12-21 |
| IL263508A (en) | 2019-01-31 |
| ZA201808258B (en) | 2022-04-28 |
| JP2019518038A (en) | 2019-06-27 |
| BR112018075660A2 (en) | 2019-04-09 |
| RU2019100220A3 (en) | 2020-12-24 |
| KR20230047210A (en) | 2023-04-06 |
| AU2017283491B2 (en) | 2021-06-03 |
| EP3468548A1 (en) | 2019-04-17 |
| MX2018015172A (en) | 2019-07-04 |
| IL263508B2 (en) | 2023-06-01 |
| AU2017283491A1 (en) | 2018-12-20 |
| CA3026515A1 (en) | 2017-12-21 |
| EP3468548B1 (en) | 2021-08-04 |
| JP2020147602A (en) | 2020-09-17 |
| KR20190017913A (en) | 2019-02-20 |
| JP7083214B2 (en) | 2022-06-10 |
| JP2020147601A (en) | 2020-09-17 |
| EP3468548A4 (en) | 2020-01-22 |
| SG11201810940XA (en) | 2019-01-30 |
| RU2019100220A (en) | 2020-07-15 |
| RU2768479C2 (en) | 2022-03-24 |
| CN109562086A (en) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258098A1 (en) | Methods of treating cancer | |
| IL275663A (en) | Methods of treating cancer | |
| HK1251409A1 (en) | Methods of treating cancer | |
| IL269026A (en) | Methods of treating tumor | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL263925A (en) | Methods of treating ovarian cancer | |
| IL262342A (en) | Methods of treating cancer | |
| ZA201808258B (en) | Methods of treating pancreatic cancer | |
| IL264443A (en) | Methods of treating prostate cancer | |
| HK1251927A1 (en) | Novel biomarkers and methods of treating cancer | |
| EP3325006A4 (en) | Methods of treating cd166-expressing cancer | |
| ZA201908539B (en) | Method of treatment of cancer | |
| EP3487999A4 (en) | Methods of treating cancer | |
| SG11202005163PA (en) | Methods of treating cancer | |
| IL267613A (en) | Treatment of pancreatic cancer | |
| GB201717945D0 (en) | Method for treatment of cancer | |
| EP3200801A4 (en) | Methods of treating pancreatic cancer | |
| IL269123A (en) | Methods of treating cancer | |
| IL272379A (en) | Methods of treating cancer by inhibiting setd2 | |
| GB201510197D0 (en) | Method of treating ovarian cancer | |
| GB201702139D0 (en) | Methods of cancer treatment | |
| GB201604293D0 (en) | Treatment of cancer | |
| GB201507937D0 (en) | Compounds for treatment of pancreatic cancer |